MTVA earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -0.26. Updated 2026-07-23.
MetaVia (MTVA) Research Hub
MetaVia (MTVA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.66 USD (-4.60%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.26, market cap 0.00B. This hub links to the full technical, earnings and options research available for MTVA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.66 USD (-4.60%) |
| 52-week range | 1.38 USD – 2.61 USD |
| Trend regime | Range |
| 14-day RSI | 60.8 (Bullish) |
| Trailing P/E | -0.26 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for MTVA
Covered Call on MTVA: how it works, illustrative setup around the real 1.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MTVA: how it works, illustrative setup around the real 1.66 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MTVA: how it works, illustrative setup around the real 1.66 USD price, max profit/loss, breakeven and when to use it. Educational.
MTVA technical analysis: range, last 1.66 USD, RSI 60.8, 52w range 1.38 USD–2.61 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MTVA in?
MetaVia (MTVA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MTVA in an uptrend or downtrend?
As of 2026-09-11, MTVA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MTVA's trailing P/E ratio?
MTVA's trailing P/E is -0.26, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does MTVA next report earnings?
MTVA is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.85 USD.